上海中信国健药业股份有限公司 上海中信国健药业股份有限公司（以下简称“中信国健”）是由中国中信集团有限公司旗下中信泰富有限公司投资控股的生物医药高新技术企业。公司自2002年创建以来，专注于抗体药物的研发、中试和产业化，现已发展成为国内抗体制药领域的领军企业，提供覆盖治疗肿瘤、自身免疫性疾病、抗器官移植排斥反应等重大疾病领域的靶向药物。 作为一家以研发为基础的生物制药公司，中信国健已成功构建了抗体药物开发和产业化平台并掌握核心技术，具备持续开发新药的创新能力。公司生产规模位居行业前列。  ShanghaiCPGuojianPharmaceuticalCo.,Ltd.(CPGJ)isahigh-techbio-pharmaceuticalcompanywhichisco-investedandledbyChinaInternationalTrustandInvestmentCorporation(CITIC)Group.CPGJfocusesonR&D,pilotdevelopment,industrializationandcommercializationofmonoclonalantibodydrugs.Establishedin2002andgoingthroughmorethantenyearsofgrowth,CPGJhasbecomealeadingplayerinChina’sdomestictherapeuticMabarea.IthasbuiltupthelargestproductioncapacityformonoclonalantibodydrugsinChinaandfurtherexpansionisundergoingwithinCPGJ’sstrategicplanning.Thecompany’sproductpipelinehascoveredthetherapeuticsolutionsforcriticaldiseasesinOncology,TransplantationandAutoimmuneDisorders.Itsdrugforrheumaticdiseasehasmaintainedaleadingdomesticmarketshareinthebiologicalanti-rheumaticdrugsfieldinChina. DedicatedtosharpeningitsResearch&Developmentcapability,CPGJhassuccessfullyproducedkeytechnologicalknow-howsforthedevelopmentandindustrializationofmonoclonalantibodydrugs.AsCPGJ’swhollyownedR&Dorganization,BiotechnologyInstituteofShanghaiCPGuojianfocusesondiscoveryandearlydevelopmentoftherapeuticantibodiesandproteins,aswellasinnovationoftechnologiesandprocessestosupportdrugdevelopment.TheinstitutehasestablishedacomprehensivetechnologicalplatformwithastrongcapabilitytotakeadrugdevelopmentprogramfromearlydiscoverythroughCMCstage. 现由于公司发展需要，诚聘具有创新精神和成就事业理想的优秀人才加盟。 请符合条件的应聘者将中英文简历等信息发送E-mail至：******（请在邮件题目上注明应聘职位等信息）